These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22403424)

  • 21. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
    Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
    J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
    Boyd SD; Maldarelli F; Sereti I; Ouedraogo GL; Rehm CA; Boltz V; Shoemaker D; Pau AK
    Antivir Ther; 2011; 16(2):257-61. PubMed ID: 21447876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
    Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
    J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.
    Young TP; Cloherty G; Fransen S; Napolitano L; Swanson P; Herman C; Parkin NT; Hackett J
    J Clin Microbiol; 2011 Apr; 49(4):1631-4. PubMed ID: 21289145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.
    Rusconi S; Vitiello P; Adorni F; Bruzzone B; De Luca A; Micheli V; Meraviglia P; Maserati R; Di Pietro M; Colao G; Penco G; Di Biagio A; Punzi G; Monno L; Zazzi M;
    Clin Microbiol Infect; 2013 Oct; 19(10):936-42. PubMed ID: 23289841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.
    Passaes CB; Guimarães ML; Fernandez SL; Lorete Rdos S; Teixeira SL; Fernandez JC; Morgado MG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):7-12. PubMed ID: 19262402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
    Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
    AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
    Reuman EC; Bachmann MH; Varghese V; Fessel WJ; Shafer RW
    Antimicrob Agents Chemother; 2010 Feb; 54(2):934-6. PubMed ID: 19917747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.
    Sierra S; Lübke N; Walter H; Schülter E; Reuter S; Fätkenheuer G; Bickel M; da Silva H; Kaiser R; Esser S;
    Med Microbiol Immunol; 2011 Nov; 200(4):225-32. PubMed ID: 21475993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.